The Circular is an important legal basis for attracting investment activities and transferring technology for drug production, especially original brand-name drugs, patented drugs, specialized drugs, special treatments, generic drugs with high-tech dosage forms, vaccines, reference biological products, and similar biological products according to the orientations in the "Program for developing the pharmaceutical and medicinal materials industry produced domestically by 2030, with a vision to 2045" approved by the Prime Minister in Decision No. 376/QD-TTg dated March 17, 2021.
With the provisions of Circular 16/2023, enterprises that process and transfer drug production technology to Vietnam will be facilitated in carrying out drug registration procedures, shortening administrative procedures and file processing time, and at the same time, being considered and applied incentives in participating in bidding for drug supply to medical facilities.
The implementation of the provisions in this circular will also create opportunities for Vietnamese pharmaceutical manufacturing enterprises to receive advanced and modern pharmaceutical production processes, technologies and techniques, making the most of production capacity, while ensuring initiative in the production and supply of high-quality drugs, vaccines and biological products for people's medical examination and treatment.
Source link
Comment (0)